Get the Stockscreener App
4.11
4.05%
0.16
After Hours:
4.15
0.04
+0.97%
Maravai Lifesciences Holdings Inc stock is traded at $4.11, with a volume of 5.44M.
It is up +4.05% in the last 24 hours and down -21.41% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
See More
Previous Close:
$3.95
Open:
$4.05
24h Volume:
5.44M
Relative Volume:
2.77
Market Cap:
$582.98M
Revenue:
$288.95M
Net Income/Loss:
$-119.03M
P/E Ratio:
-4.5641
EPS:
-0.9005
Net Cash Flow:
$60.67M
1W Performance:
-2.14%
1M Performance:
-21.41%
6M Performance:
-53.19%
1Y Performance:
-21.86%
1-Day Range:
$3.93
$4.30
1-Week Range:
$3.93
$4.40
52-Week Range:
$3.93
$11.55
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
4.11 | 582.98M | 288.95M | -119.03M | 60.67M | -0.9005 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Maravai LifeSciences (NASDAQ:MRVI) Hits New 1-Year LowHere's What Happened - MarketBeat
Investors Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - Armenian Reporter
Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Thursday - Defense World
Maravai LifeSciences Target of Unusually High Options Trading (NASDAQ:MRVI) - Defense World
Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Thursday - MarketBeat
MRVI stock touches 52-week low at $4.04 amid market challenges By Investing.com - Investing.com South Africa
MRVI stock touches 52-week low at $4.04 amid market challenges - Investing.com
Choreo LLC Sells 26,716 Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Sets New 12-Month LowTime to Sell? - MarketBeat
Maravai Lifesciences stock hits 52-week low at $4.19 - MSN
Bleakley Financial Group LLC Grows Position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - Defense World
Reviewing Maravai LifeSciences (NASDAQ:MRVI) and MBX Biosciences (NYSE:MBX) - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 6.5%Here's Why - MarketBeat
Market Highlights: Maravai LifeSciences Holdings Inc (MRVI) Ends on a Low Note at 4.58 - The Dwinnex
Maravai LifeSciences (NASDAQ:MRVI) & MBX Biosciences (NYSE:MBX) Critical Comparison - Armenian Reporter
It is Poised to be a Bull Market for Maravai LifeSciences Holdings Inc (MRVI) - SETE News
Investors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Positive Sentiment Still Eludes Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Following 25% Share Price Slump - Simply Wall St
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Hold" by Analysts - MarketBeat
A Look at Maravai LifeSciences Holdings Inc (MRVI) Shares in the Recent Past Indicates Growth - SETE News
Stock Traders Purchase Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI) - Defense World
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Rating of “Hold” by Analysts - ETF Daily News
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of “Hold” by Brokerages - Defense World
Understanding the 8.92% Volatility Levels of Maravai LifeSciences Holdings Inc’s (MRVI) Stock in the Past 30 Days - The News Heater
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology - Marketscreener.com
Breakthrough mRNA Deal: TriLink's CleanCap Tech Powers Next-Gen Clinical Development at Aldevron - StockTitan
Maravai LifeSciences Holdings Inc (MRVI) receives a Neutral rating from Guggenheim - Knox Daily
Maravai LifeSciences Holdings Inc’s results are impressive - US Post News
Ratio Analysis: Unpacking Maravai LifeSciences Holdings Inc (MRVI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Insider Selling: Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) General Counsel Sells 25,000 Shares of Stock - MarketBeat
Sivik Global Healthcare LLC Cuts Holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) - MarketBeat
TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe - Yahoo Finance
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Down 7.1%Should You Sell? - MarketBeat
Press Release Service: Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies - CRISPR Medicine News
Maravai LifeSciences expands mRNA manufacturing with new acquisition By Investing.com - Investing.com Australia
Maravai Lifesciences Acquires Molecular Assemblies' Intellectual Property, Related Assets - Marketscreener.com
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies - Business Wire
12 West Capital Management LP Reduces Stake in Maravai LifeSciences Holdings Inc - GuruFocus.com
Game-Changing DNA Synthesis Tech Could Revolutionize CRISPR Therapy Production - StockTitan
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat
Traders Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - Defense World
Maravai LifeSciences (NASDAQ:MRVI) Stock Price Up 9.5%Here's Why - MarketBeat
Maravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential - Yahoo Finance
12 Stocks Under $5 With Biggest Upside Potential - Insider Monkey
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpTime to Buy? - MarketBeat
Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 43%? - Simply Wall St
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):